$1.52
+0.00 (+0.00%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALZN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 with posted results
Held by 0 tracked-famous managers · FINRA short interest 4.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study in Subjects With Mild-to-Moderate Alzheimer's DementiaNCT05834296TEAEsRandomized · Triple-masked · Treatment | Phase 1/2 | Active, not recruiting | Biological: ALZN002 (autologous DCs pulsed with E22W mutant peptide). · Drug: Placebo | Alzheimer Disease | 30 | 2028-03-03 | in 561 d | 2025-09-02 |
| A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderNCT07540338To evaluate differences in brain and/or brain structure lithium PK relative to plasma PK for AL001 capsule compared to a lithium carbonate capsule.Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: AL001, Lithium carbonate | Bipolar I Disorder | 20 | Dec 2026 | ≤ 133 d | 2026-07-28 |
| A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult SubjectsNCT06921590To evaluate differences in brain and/or brain structure lithium PK relative to plasma PK for AL001 capsule compared to a lithium carbonate capsule.Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 1 | Completed | Drug: AL001, Lithium Carbonate Capsule | Pharmacokinetics, Neurology | 15 | 2025-12-15actual | — | 2026-07-29 |
| Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult SubjectsNCT05363293results2025-05-14Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings.Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: AL001 · Other: Placebo | Alzheimer's Disease, Healthy Non-elderly and Elderly Adults | 65 | 2023-04-14actual | — | 2025-05-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19